G1 Therapeutics (GTHX)
(Real Time Quote from BATS)
$7.14 USD
-0.01 (-0.14%)
Updated Sep 16, 2024 01:22 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 201 - 220 ( 361 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
More Positive Data for Trilaciclib in mTNBC and Rintodestrant at SABCS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Final Trilaciclib in mTNBC OS Data and New Rintodestrant Monotherapy in ER+, HER2- Breast Cancer Findings at 2020 SABCS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Rinto Update in Q4, Trila PDUFA February 15th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q20 Results; Approval and Launch of Trilaciclib Expected 1Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Rinto Update in Q4, Trila PDUFA February 15th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Abstracts Released for Trilaciclib Presentations at the North American Conference on Lung Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E